Hospitalpharma.com: The online resource for hospital pharmacy

Areas of this site are restricted to registered users only.
Please log in.
Not Registered?
Click here.
Forgotten Password?

username:

Password:

Resources | Features

submit a feature

What's new in...all features \| 454 Features \| view archive
	Anti-Obesity Treatments 2007-2012 09 May 08 “By 2010, almost 50 percent of children in North America and 38 percent of those in the European Union will be overweight, research has found”. For pharmaceutical companies looking to target growing successful markets, the anti-obesity drug treatment market offers unique opportunities. Nini Wei- Visiongain Ltd
	What Is Crohn's Disease? 07 May 08 Pharmiweb editor
	What is obesity? 06 May 08 Obesity is the heavy accumulation of fat in your body to such a degree that it rapidly increases your risk of diseases that can damage your health and knock years off your life, such as heart disease and diabetes. pharmiweb editor
	Medical and Healthcare Business Reacting Bullishly to the Credit Crunch 16 Apr 08 Despite the pressures, medical and healthcare businesses appear to be reacting bullishly to the credit crunch according to a new study released today. When asked if they had to start their business again in today’s economic climate, 78% of medical and healthcare businesses would do it all again tomorrow. David Barrett
	Blood Disorders Market 16 Apr 08 In 2007, blood diseases cost the US’s economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments. Justyna Drozdzal
	The Hygiene Hypothesis 15 Apr 08 Why do some people have allergies and some not? And why has the prevalence of allergic disorders been increasing over the past century, especially in industrialised, developed countries? Mike Wood
	Sleep Disorders Market Analysis 2008-2018 11 Apr 08 Which current or future therapies will drive the sleep disorders market from 2008 to 2018? What is the patient identification rate for each of the therapeutic areas? What is the present state of the disease awareness? What R&D opportunities exist for ‘new comers’? Which key companies are involved in the market? Justyna Drozdzal
	Embarrassed to blow your nose? 01 Apr 08 Forget sweat patches, VPLs and spots…a new survey commissioned by Kleenex® has found that it’s blowing your nose in public that causes us the most embarrassment! The survey of hay fever sufferers reveals that most people prefer a quiet sniff over a good nose blow when out and about. However, allergy specialists warn that the more discreet option actually makes symptoms worse. Jasmine Richards
	Increasing numbers of people are suffering from Asthma 31 Mar 08 Asthma is a significant health problem. Acording to the National Asthma Campaign, the condition continues to grow, and in the UK an estimated 8 million people are diagnosed as having asthma, with 5 million people receiving treatment. The cost of asthma to the NHS is more than £850 million a year. Mike Wood
	ExL Pharma presents: The 3rd Annual Integrated Relationship Marketing and Sales for Pharma 31 Mar 08 ADVANCED COMMUNICATION TECHNIQUES FOR DELIVERING TARGETED MESSAGES AND DEVELOPING BRAND LOYALTY Matt Milman
	Bell Pottinger EXPANDS healthcare business 25 Mar 08 Bell Pottinger Group has formed Bell Pottinger Health, a new business dedicated to leading the expansion of its health franchise with Shipra Singh newly hired as Managing Director. Simultaneously the company has brought in a life science investor relations team led by Mike Wort. Deborah Cockerill
	Versatility: The Key to Pharmaceutical Sales Performance 22 Mar 08 While having a sales force that can deliver your company¡¦s message to physicians and other health care professionals is critical to effective performance, the true key to success is having a sales force that can adapt that message to the needs and preferences of those they call on. Wilson Learning¡¦s research shows that versatile salespeople can be over 50% more successful than their less adaptable counterparts. This was effectively demonstrated in a study with a large pharmaceutical company. Natalie Barlow
	Chiltern wins 4 'Pharmas' 12 Mar 08 Chiltern, a leading global research organization, is proud to announce that it won 4 ‘Pharmas’ at the PharmaTimes Clinical Researcher of the Year ceremony, including the coveted Clinical Department of the Year. Peter Lewis
	Movers and Shakers - Richard Wallace 21 Feb 08 Bridgehead International Board Appointment – February 2008 Richard Wallace joins Bridgehead International Board Sandra Church
	Is that a Smartphone in your pocket, or are you just pleased to see me? 20 Feb 08 In case you hadn’t noticed, mobile phone manufacturers – and the operators – are desperate to part you from your cash in return for a flash new device. So, to help you decide if you should give in to temptation, we have reviewed three of the latest smartphones that the market has to offer. PharmiWeb.com - editor
	Health Effects of Climate Change in the UK 15 Feb 08 Climate change will have consequences for the health of UK citizens according to a UK government report published on 12th February. The report, called Health Effects of Climate Change in the UK, has been published jointly by the Department of Health (DH) and the Health Protection Agency (HPA). PharmiWeb.com - editor
	The Golden Keys of E-Commerce 09 Jan 08 The issue of climate change is now upon us....and the news about ecology is unfolding with many variables. Here is my take on the image and branding side. Naseem Javed
	Almirall reveals leading edge inhaler for new COPD drug aclidinium bromide 04 Dec 07 Spanish pharmaceutical company Almirall has unveiled a state-of-the-art new dry-powder inhaler in which it plans to market its lead pipeline compound aclidinium bromide for chronic obstructive pulmonary disease (COPD). The device, developed by specialist inhaler company Sofotec, acquired by Almirall in 2006, is set to become the gold standard in inhaler design, claims the company, and will aid patient compliance with anticholinergic medication. Olwen Glynn Owen - Pharmiweb Field Reporter
	Pharma ROI – RIP or SOP? 27 Nov 07 PharmiWeb Solutions’ Managing Director Paul Hartigan was a speaker at the annual conference of the Pharmaceutical Marketing Society in London yesterday, November 26th, hosted by the Royal College of Nurses. He reviews his thoughts on the day here. Editor
	More data confirm DPP-4 inhibitor vildagliptin (Galvus) offers special advantages for elderly Type 2 diabetes patients 24 Sep 07 Olwen Glynn Owen - Pharmiweb Field Reporter
	PharmiWeb Solutions shortlisted for the Best Online Publisher awards 06 Sep 07 Healthcare specialist online publisher and e-business services provider PharmiWeb Solutions has been shortlisted for the Best Online Publisher awards by the UK Association of Online Publishers (AOP). Paul Hartigan, PharmiWeb CEO, commented on the news, which was announced this week, “We’re delighted to be shortlisted for such a prestigious award. Colin Williams
	Novartis, Takeda and B-MS challenging Merck’s market exclusivity in DPP-4 market 07 Aug 07 Merck’s position as the sole provider of an oral antidiabetic drug in the novel dipeptidyl peptidase 4 (DPP 4) inhibitor class is under challenge as at least three companies – Novartis, Takeda and Bristol-Myers Squibb - enter the final stretch of the development process. All four companies presented new data at this year’s American Diabetes Association meeting in Chicago. Olwen Glynn Owen
	BIPOLAR DISORDER: a new holistic approach 30 Jul 07 BIPOLAR DISORDER: a new holistic approach to controlling mood disturbance from multiple aspects could revolutionise patients’ prospects Olwen Glynn Owen
	Wyeth Reports Earnings Results for the 2007 Second Quarter and First Half 25 Jul 07 Madison, N.J., July 19, 2007 - Wyeth (NYSE: WYE) today reported results for the 2007 second quarter and first half ending June 30, 2007. Worldwide net revenue increased 10% to $5.6 billion for the 2007 second quarter and 10% to $11.0 billion for the 2007 first half. Excluding the favorable impact of foreign exchange, worldwide net revenue increased 7% for the 2007 second quarter and 8% for the 2007 first half. Douglas Petkus
	114 Blockbuster Drugs Accounted for 2006 Sales of US$ 233.7 bln 24 Jul 07 The best selling blockbuster drug in 2006 was atorvastatin from Pfizer and Astellas Pharma with ww sales of US$ 13.6 bln. Biologics made 23.1 % of the total blockbuster drug sales of US$ 233.7 bln generated by 114 blockbuster drugs from 30 companies. Pau Cuevas
	Avastin® receives positive opinion in Europe for first-line treatment of patients with advanced lung cancer 20 Jul 07 First medicine shown to extend survival of previously untreated lung cancer patients beyond one year. Erica Bersin
	Market Leading Pharmaceutical Recruitment Consultancy Barrington James Limited is happy to announce the appointment of Tony Kelleher as its Sales Manager 02 Jul 07 Barrington James Limited currently places candidates extensively throughout the UK and Europe in many areas such as Clinical Research, Regulatory Affairs, Medical Affairs, Data Management and Business Development. Working with key Barrington James Team Leaders such as Paul Duffy, Tony Kelleher will be charged with growing the team to assist with their Client’s needs throughout Europe. Dan Barrington, Director, said “…we are delighted Tony agreed to join Barrington James Limited, he brings Dan Barrington
	Sales Force Effectiveness in Asia-Pacific: Free report 12 Jun 07 This free report looks into the huge opportunities and challenges available to pharmaceutical companies when it comes to increasing sales force effectiveness in the Asia-Pacific region. Download the report here - http://www.eyeforpharma.com/sfeapac/report.shtml Lisa Roner, eyeforpharma
	Erbitux moves to front-line in attack against both metastatic head and neck and colorectal cancers 11 Jun 07 The anti-EGFR targeting cancer therapy Erbitux (cetuximab), has been approved in Europe for the treatment of locally advanced head and neck cancer in conjunction with radiotherapy and as a third-line treatment in combination with irinotecan-based chemotherapy for patients with metastatic colorectal cancer. New data from the phase III EXTREME and CRYSTAL trials, presented at the American Society of Clinical Oncology’s annual meeting, show cetuximab added to chemotherapy is also an effective first Olwen Glynn Owen
	Sponsor a CEO 11 Jun 07 Those of you who know our CEO Paul Hartigan will realise that he is a keen cyclist (we have to repeatedly ask him not to turn up to customer meetings in some of his garishly coloured Lycra). Editor
	CRYSTAL trial reveals benefits of first-line cetuximab in mCRC 08 Jun 07 Results of the CRYSTAL trial investigating first-line cetuximab therapy in addition to irinotecan-based therapy in metastatic colorectal cancer (mCRC) were presented by the study’s lead investigator, Professor Eric Van Cutsem of University Hospital, Gasthuisberg, Leuven, Belgium. Olwen Glynn Owen
	Lhasa Acts in Support of Science Education in Africa 05 Jun 07 In 2007 Lhasa will provide sponsorship to the Africa Education Initiative (NEF) for travel fellowships allowing African students to attend the 2007 Africa Education Initiative International Scientific Conference. Lhasa Limited
	BENEFiT study shows Tracleer (bosentan) improves haemodynamics in CTEPH patients refused surgery 04 Jun 07 Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) who miss out on potentially curative surgery may respond to medical treatment with the dual endothelin receptor antagonist bosentan (Tracleer) according to results of BENEFiT, a multicentre phase III trial presented at this year’s American Thoracic Society meeting. To date there has been no approved medical therapy for the condition. Olwen Glynn Owen
	Revised Version:The imminent change of the antithrombotics market 30 May 07 The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio La Merie Business Intelligence
	The imminent change of the antithrombotics market 30 May 07 The antithrombotics market with the two blockbusters enoxaparin and prasugrel is challenged by generic products as well as by next generation anticoagulants with oral administration and antithrombotics with an improved risk-benefit ratio La Merie Business Intelligence
	So you want to contract staff… what do you need to consider? 23 May 07 In today’s clinical arena it is the norm for clinical and medical departments to work with a mixture of direct staff (headcount), contract employees and independent consultants, as well as outsourcing whole projects. Companies utilise this mix for myriad reasons, including increased pressure to reduce headcount carrying costs demands for flexibility and to meet the clinical trial program milestones within a reduced time to market. Paula Mumby
	What’s Up (Junior) Doc? 22 May 07 With in excess of 34,000 doctors chasing 18,500 training posts due to start in August, one might expect that a slick system would be employed to ensure that the best candidates were matched with the most appropriate jobs. And maybe that’s what the MTAS (the Medical Training Application Service - an online application system designed to allow juniors to apply centrally for training rotations) was meant to achieve. However, it had been prone to crashing, and many junior doctors claimed that it was Paul Hartigan
	The Newspaper Cemetery 14 May 07 Despite all denials, newspapers all over the world are simply dying. The gravity of the problem is not that the competing media like TV or Internet are at play it’s rather that the public all over the world prefers moving pictures in the palms of their hands over deciphering or reading between the lines of nicely arranged words spread out on a paper blanket. Naseem Javed
	Visit Lhasa Limited at the 55th ASMS Conference on Mass Spectrometry (Booth # 112) 04 May 07 June 3 - 7, 2007 Indiana Convention Center, Indianapolis, Indiana, USA Members of the Lhasa Limited sales team will be attending this year’s ASMS sponsored Annual Conference on Mass Spectrometry and Allied Topics. The event is attended by almost 6,000 scientists and over 2,000 papers are presented alongside posters and talks. Marketing Team
	Up and down with cholesterol management 02 May 07 Sales of statins have reached a plateau, the imminent decline may be slowed by combination with cholesterol absorption inhibitors; future direction of R&D is focused on increasing HDL cholesterol. La Merie Business Intelligence
	Beyond biogenerics: the real threats for therapeutic proteins 25 Apr 07 The biogenerics industry consolidates with Indian players emerging in Western countries; pegylation, protein engineering, drug delivery and oral small molecules feed the pipeline of next generation competitors of therapeutic proteins La Merie Business Intelligence
	Wyeth’s Winning Ways: Big Pharma Bounces Back 20 Apr 07 After a year or so of relatively disappointing results from Big Pharma, there seems to be a new wave of optimism sweeping across the industry. Paul Hartigan
	eyeforPharma announces dates for New Concept in Interactive Webinar Events to reach more pharma executives online 11 Apr 07 The Sales Technology & CRM Webinar will take place at 15.00 GMT/10.00 EST, 24th May 2007 Richard Bracchi
	A Gala Tribute to Global Copycats 03 Apr 07 Over the decade, the art of copying and stealing other people's content and ideas has settled comfortably in the mainstream across the globe. What formerly would constitute an act of piracy is now a commonplace, everyday occurrence. Isn't it time to give these 'borrowers' a tribute, host a gala dinner and hand out awards? Naseem Javed
	Pharmiweb e:HR Awards 03 Apr 07 PharmiWeb Solutions – online publisher and e-business solutions provider to the pharmaceutical sector – recently announced the results of its inaugural PharmiWeb.com Annual e:HR Europe Awards. Mike Wood
	Levitra® - Opportunity for Proactive Generic Companies? 23 Mar 07 SYDNEY, N.S.W., 2 Mar 2007 – The recently released GenericsWeb Pipeline Developer patent report for Levitra® (Vardenafil) highlights the importance of high quality patent information when considering development of generic equivalents in the early stages of a product’s lifecycle. Leighton Howard
	Improving, developing and integrating your e-Clinical Systems... 20 Mar 07 Covering all the major topics surrounding EDC and other e-Clinical technologies, this year’s e-Clinical Trials event will also look carefully at how to integrate a range of systems for a successful e-Clinical programme and bring you up-to-date on current standards and the latest technological options. Delegates will also benefit from a highly detailed interactive workshop on managing e-Clinical Trials in exotic and difficult locations. Furthermore, This year’s e-Clinical Trials conference wil Amir Sebahat
	Weight management is not enough for cannabinoid type 1 (CB1) receptor antagonists to become a commercial success 08 Mar 07 Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug La Merie Business Intelligence
	The new class of dipeptidyl peptidase IV (DPP-IV) inhibitors has one clear leader and many followers 01 Mar 07 Merck & Co clearly leads the field of DPP-IV inhibitors which has many followers in clinical development. The first companies already abandoned the field. La Merie Business Intelligence
	TOP Classes of Biologics with 2006 Sales of US$ 63.8 bln 26 Feb 07 Sales of the major cancer antibodies grew by 57 % to US$ 10.6 bln in 2006. Cancer antibodies are challenging the still no. 1 selling class of erythropoietins with 2006 sales of US$ 11.9 bln, but the lowest growth rate (6.4 %), and got ahead of TNF antibodies which posted sales of 10.3 bln (+ 25 %). La Merie Business Intelligence
	The market of recombinant coagulation factors is growing with next generation products 14 Feb 07 The growing market of recombinant coagulation factors posted 2006 sales of more than US$ 4.6 bln. The four market leaders compete with a staggered series of next generation products and face competition by new entrants into the various segments of the field La Merie Business Intelligence
	Dosing convenience is mandatory to keep pace in the pipeline race of GLP-1 analogs for type 2 diabetes 05 Feb 07 The emerging market of GLP-1 analogs with 2006 sales of US$ 430.2 mln in the first full market year of twice-daily exenatide attracts other players in the diabetes field, but urges them to top exenatide by more convenient products La Merie Business Intelligence
	Overview On 2006 Sales Of TOP 20 Biologics To Be Released On February 26 02 Feb 07 A free compilation of the 2006 sales of the TOP 20 blockbuster and other major recombinant antibodies and proteins will be provided by La Merie Business Intelligence starting February 26 La Merie Business Intelligence
	Reducing Risks of Infusion Related Reactions in Targeted Cancer Therapy 30 Jan 07 Infusion-related reactions occur with a wide variety of therapeutic agents used in the treatment of cancer but have become a particular concern of the targeted monoclonal antibody therapies. A post-hoc analysis performed on data from a recent large study suggests a way of minimising risk. Olwen Glynn Owen
	The iPhones, iPains & iProblems 16 Jan 07 The Appendage of the letter "i" to a word as an aim to create an icon is silly… Naseem Javed
	The right balance drives the field of PPAR agonist R&D 11 Jan 07 A strongly growing market of now more than US$ 6 bln in 2006 for only tow PPAR gamma agonists founds the basis for a heavily researched field of next generation mono, dual or triple PPAR agonists with fine-tuned subtype combinations La Merie Business Intelligence
	Eltrombopag (Promacta) offers hope of an effective oral treatment for bleeding due to thrombocytopenia 03 Jan 07 Thrombocytopenia, the bleeding disorder caused by a deficiency of platelets, has no easy-to-administer or satisfactory treatment at present. However, eltrombopag (Promacta) a new oral drug in development by GlaxoSmithKline (GSK) has progressed to phase III Olwen Glynn Owen
	Pharma turns to reformulation to maximize ROI 15 Dec 06 With drug pipelines yielding fewer blockbusters and profits from branded drugs being increasingly eroded by generic incursion, pharmaceutical companies are looking to maximize the return on investment of their drugs that do make it to market. Consequently, reformulation has become a common defense by drug makers to prolong the lifecycle of their top sellers. Datamonitor
	Patient Adherence: The Transformation of Loyalty Strategies 12 Dec 06 Frost & Sullivan, along with their panel of distinguished industry experts, will take a look at the changing dynamics in today's U.S. pharmaceutical industry. The panel will review traditional adherence programs, examine what is and is not working, and what the next steps are toward addressing the multiple barriers contributing to non-adherence. For additional information, please visit http://ebroadcast.frost.com/loyalty Brian Denker
	Antihypertensives: Generics striking at heart of the market 08 Dec 06 Despite almost 200 million people suffering from high blood pressure in the western world alone, the growth rate of the antihypertensive market is actually slowing, largely as a result of generic incursion. In fact many pharmaceutical companies, including those with strong cardiovascular portfolios, are turning their back on this market in favor of more profitable indications, such as oncology. Datamonitor
	AstraZeneca has announced that it will launch a generic version of its own heart drug Toprol XL. 24 Nov 06 AstraZeneca's third biggest-selling drug, Toprol XL, has come up against generic competition sooner than anticipated after losing its protection against copycat launches. AstraZeneca has responded by reaching an agreement with US generic firm Par Pharmaceutical to distribute and supply a 25mg generic version of Toprol XL, a strategy that could be used with its other drugs facing patent expiry. Datamonitor
	Inhalable insulin: reality doesn't live up to hype 21 Nov 06 Inhalabe insulin treatments promised to revolutionize the treatment of insulin-dependent diabetes by removing the 'injection barrier' from treatment regimes. However, while inhalable insulins will see a reasonable level of uptake, they aren't the sure fire blockbuster they were hyped to be. Datamonitor
	Asthma/COPD combination products here to stay 10 Nov 06 The treatment of asthma and COPD has dramatically improved following the increased use of fixed dose inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) combination therapies. Although Advair dominates the total asthma/COPD market, Symbicort's recent US approval and Chiesi's recent European approval of an ICS/LABA combination drug, signal a major change in the market dynamics. Datamonitor
	More to Veterinary Anthelmintic ProHeart® than Green Book Indicates 02 Nov 06 Analysis of the GenericsWeb Pipeline Patent Intelligence for Wyeth’s top selling veterinary anthelmintic ProHeart® (Moxidectin) shows that generic manufacturers should be wary of relying upon the US FDA Green Book for their critical patent expiry information. Leighton Howard
	Pfizer: still biggest player in highly prized indication 31 Oct 06 The success of neuropathic pain drug Neurontin earned Pfizer its reputation as the "neuropathic pain company" and the US pharmaceutical giant faced very little competition in a relatively untapped market for ten years. Neuropathic pain is now one of the most attractive indications in the pharmaceutical industry but Pfizer still dominates the market. Datamonitor
	The PharmiWeb.com e:HR Awards 2006 25 Oct 06 Recognizing excellence in the application of an e-business approach in pharma and biotech HR in Europe. Mike Wood
	Drug pipeline suggests glimmer of hope for SLE sufferers 20 Oct 06 While there have been no new treatments approved for systemic lupus erythematosus (SLE) in almost 40 years, there are some promising treatments currently in the development pipeline. Unfortunately, the ambiguity surrounding the requirements of clinical trials is preventing these drugs from being approved. However, faced with few alternatives, that hasn't prevented physicians using them off-label. Datamonitor
	Ovarian cancer: platinum-based therapy still the gold standard 13 Oct 06 Despite being the most common cause of death from gynecological tumors, ovarian cancer does not attract the same level of R&D interest as more prevalent tumor types. While surgery still plays a central role in the treatment of ovarian cancer, platinum-based therapy, in particular, carboplatin in combination with paclitaxel, remains the mainstay of cytotoxic treatment for ovarian cancer. Datamonitor
	Schering-Plough: new fungicide gets US approval 06 Oct 06 Noxafil is a new fungicide developed by Schering-Plough. Already marketed in Europe, it has now received US approval on the basis of clinical trials showing its superiority over fluconazole in preventing invasive fungal infections in immuno-compromised patients. Revenues derived from this new drug will help bolster Schering-Plough's Infectious Diseases division. Datamonitor
	Researchers find new clue to treating diabetes 05 Oct 06 Researchers in Auckland have decoded the structure of a molecule that may provide clues for a new type of diabetes drug. Emma Timewell
	Age is no longer a factor 02 Oct 06 From October 1st 2006 the Employment Equality (Age) Regulations 2006 - is coming in to force, making it illegal in the UK to recruit or select candidates based on their age and to discriminate based on age whilst in employment rather than based on skills and competencies. This will apply to discrimination againt young and old, and it WILL dramatically affect recruitment and employment in the UK. Mike Wood
	Independent Nurse Contractor Guide 01 Oct 06 Nurses want Independence, Respect and Higher Income If you love your nursing career and are frustrated with your current nursing job than this is the answer for you. As an Independent RN Contractor you will achieve financial freedom, improved nursing career opportunities and recognition of your worth. In short as a nurse entrepreneur we have increases job satisfaction,more money, better hours, and increased choices; as to how, when and where you practice http://www.independentrncontractor.com Mericle RN Staffing LLC
	Mid pharma looks outside itself to drive revenue 28 Sep 06 In 2005, 44% of 'mid pharma' revenues were derived from products that have been discovered outside of the in-house development pipelines. In fact, even in the absence of any further external sourcing between now and 2010, the dependence on revenues of products that came from external pipelines will continue to increase, coming to stand at 49% by 2010. Datamonitor
	DPP-4 inhibitors Galvus and Januvia will be the first oral drugs tackling Type 2 diabetes via the incretin response: how do they compare? 27 Sep 06 A new DPP-4 inhibitor class of oral anti-diabetic medicines, working by the novel mechanism of incretin enhancement, is poised to revolutionise the management of Type 2 diabetes. Data presented at a recent European Association for the Study of Diabetes meeting suggest they will help fill the unmet need for effective anti-diabetic drugs without unacceptable side effects. Numerous agents are in development with two, Galvus (vildagliptin, Novartis) and Januvia (sitagliptin, Merck) awaiting approval Olwen Glynn Owen - PharmiWeb Field Reporter
	International Conference on Silicone Elastomes Highlights Future Growth 25 Sep 06 Rapra Technology’s First International Conference on Silicone Elastomers took place in Frankfurt on 19-20 September attracting over 120 delegates from as far away as Australia, Brazil, Russia and the US. Presentations covered silicone elastomer materials, liquid silicone rubber, the processing of silicone elastomers, additives and finishing for silicone elastomers. Delegates praised the breadth of the programme content and the practical nature of many of the papers. Sharon Garrington
	The dangers of counterfeit anti-infectives 22 Sep 06 Counterfeit anti-infective drugs are a serious issue, causing significant morbidity and mortality, particularly in poorer countries, and having a huge financial impact on pharmaceutical firms worldwide. To make matters worse, high-tech solutions proposed and applied in the developed world are not easily transferable to the regions of Africa and Asia, where more than 50% of drugs may be fake. Datamonitor
	GSK: given green light to restrict Greek drug supply 20 Sep 06 The Hellenic Competition Committee has issued GSK with a favorable decision, indicating that it can restrict the supply of pharmaceuticals to wholesalers to prevent parallel importation of these drugs, without breaking competition laws. This is an important step for legally restricting parallel importation from one of Europe's biggest parallel trade markets, as Datamonitor's Dr Mark Belsey discovers… Datamonitor
	Delivery improvements of the AMD-drug Lucentis on the way 20 Sep 06 The anti-VEGF Fab Lucentis is the new standard of care to treat AMD because it can improve visual acuity. Competitor drugs directed against the same and innovative targets are applied with non-intravitreal forms of administration to avoid the unease of intra-vitreal injection La Merie Business Intelligence
	Meet the Country 20 Sep 06 Running clinical trials and recruiting experienced clinical personnel in the UK has certainly challenged many senior managers and recruiters over the past year. At a recent UK conference, both the Association of the British Pharmaceutical Industry (ABPI) and a UK pharmaceutical website were quoted as stating that there continues to be a skills shortage across all disciplines; a lack of long-term educational investment and less development of the existing talent pool were cited as the main reaso Iain Jessup
	PHASE IV CLINICAL TRIALS: Post Marketing Studies 19 Sep 06 Strategic Research Institute’s Phase IV Clinical Trials (PCT) conference features a fully packed informational two day event organized into a series of discussions focusing on the major Phase IV and Patient Recruitment/ Retention issues of today. Amy Yueh
	Pay for Performance: Strategies for Achieving Value and Improving Health Outcomes 19 Sep 06 GAIN VALUABLE INSIGHT INTO: • How CMS’ movement toward P4P will Impact Healthcare and Payors Nationwide • Large Employer HR Strategy: How Aligning Incentives and Creating a Health • Information Exchange will Reduce your Healthcare Spend • Health Plans: How Data, Transparency and Consumers will Affect your P4P Initiatives Seth Fritts
	Medicare Part D: What is the Future? 19 Sep 06 Highlights Include: Five Presentations from CMS including an Update on the 2007 Landscape Understanding the Short- and Long-Term Impact of Part D Strategies for Driving Senior Enrollment Innovative Approaches to Public & Private Partnerships Analyzing Patient Perceptions of Out-of-Pocket Costs The Importance of Pharmacoeconomic Data Securing Favorable Formulary Coverage in the Part D Environment The Future of Employer Plans Amy Yueh
	Bridging the Skills Gap - The i3 Pharma Resourcing Partnership Training Programme 11 Sep 06 i3 Pharma Resourcing focuses on the provision of high calibre clinical research personnel to the pharmaceutical industry, via our permanent and contract resourcing services. If you have recently been involved in the recruitment of clinical research staff, you will be aware that there continues to be a shortage of trained, experienced CRAs. With pressures on both human and financial resources throughout the industry, new staff are required to “hit the ground running”. Monica Evans
	ICON expands experience in the development of new cancer therapies 11 Sep 06 A new generation of oncology drugs is proving highly effective against certain cancers. Icon
	Biologics define new standard of therapy in psoriasis 07 Sep 06 Anti-TNF agents set the new gold standard of psoriasis treatment which could be outperformed by smarter next generation biologics and small molecules in safety and convenience La Merie Business Intelligence
	Avandia Patents Afford Protection Against Generic Competition 06 Sep 06 Generic pharmaceutical manufacturers should proceed with caution when developing generic versions of Avandia®, (Rosiglitazone maleate), according to experts at GenericsWeb... Leighton Howard
	We are opening our doors here at i3 31 Aug 06 We would like to invite you to join us here at our offices in Maidenhead, Berkshire from 10.30 onwards to 14.30. Sarah Kettlewell
	Lean Documentation 5 30 Aug 06 In an earlier field report, we looked at some of the issues surrounding manufacturing process instructions (MPIs) and manufacturing process records (MPRs). I want to look at the issue of recording data in MPRs in more detail, as the format of your MPR has a huge impact on its usability and therefore the error rate. PharmiWeb.com Field Reporter: Jo Hills
	Movers and Shakers of the Pharma Industry - Paul Hawkins 23 Aug 06 Paul Hawkins, the General Secretary for the Health and Beauty Association, tells us his philosophy for career progression and how the H&BA’s new website will help them to progress. The website itself promotes HBA’s attempt to bring Health and Beauty companies together in debating and discussing how to develop and adapt the industry to meet changing customer and consumer needs. Paul hopes the move towards e-business will do just that. Freya Eden-Ellis
	Graduates Entering the Pharmaceutical Industry 22 Aug 06 You may not exactly be breaking into the gold vaults at Fort Knox, scaling the heights of MI5 à la James Bond or hacking into The Pentagon security system, but you want to enter the pharmaceutical industry, which can be nearly as difficult. Freya Eden-Ellis
	US healthcare payers turn to reimbursement to contain costs 18 Aug 06 With overall healthcare spending set to continue rising, payers are implementing cost containment measures, increasing the importance of developing a robust and flexible pricing and reimbursement (P&R) strategy. In formulating and adapting a P&R strategy, it is vital for drug developers to understand how P&R fits into the US healthcare market, and to identify the different types of P&R controls. Datamonitor
	AstraZeneca's Symbicort the first of many new combination drugs to come 10 Aug 06 AstraZeneca has received FDA approval for its combination asthma drug Symbicort, which will now enter a fiercely competitive market, to face not only GlaxoSmithKline's blockbuster Advair but also new combination drugs, which are expected to steal market share from 2010. However, as Datamonitor's Lisette Oversteegen explains, Symbicort's SMART approach could be key to overcoming these challenges. Datamonitor
	Advanced Forum on IPR in CHINA 09 Aug 06 The protection of intellectual property (IP) rights has become crucial to the success of many foreign investors and enterprises who wish to profit from China’s fast growing market. As many foreign investors have discovered that counterfeiting, passing off and other forms of IP infringement are common in China. At the same time, Chinese companies are investing heavily in sophisticated technology and require an effective IP system to protect their own investment. The dynamics of protecting inte Jones Days
	Candidate Profile: Paul Collins 09 Aug 06 Candidate Profile: Paul Collins Current Job Title: Clinical Project Manager II Department: Clinical Commenced with ICON: July 1997 Mike Wood, Freya Eden-Ellis
	Movers and Shakers of the Pharma Industry - Andy Sarfas 08 Aug 06 Andy Sarfas is our mover and shaker of the week. He is the Global Internet Business Manager for Reckitt Benckiser. Freya Eden-Ellis
	Movers and Shakers of the Pharma Industry - David Mitchell 08 Aug 06 David Mitchell is the Commercial Director at McNeil Consumer Healthcare, a company that produces remedies for self-treatment available at pharmacies and supermarket stores. Freya Eden-Ellis
	Movers and Shakers of the Pharma Industry - Alex Bishop 08 Aug 06 Alex Bishop is the IT Business Manager at Pfizer, the largest supplier of medicines to the NHS. Freya Eden-Ellis
	Diverse challenges await generics industry 04 Aug 06 Because of the ever-increasing costs of healthcare provision the world over, many governments are enacting legislation to promote generic prescription in order to keep costs down. With drugs worth $160 billion in sales coming off patent by 2015, it would seem a good time to be in the generics industry. However the generics market is not without challenges. Datamonitor
	Lean Documentation 4 03 Aug 06 Manufacturing Instructions and Records: Operators are expected to follow manufacturing instructions to produce a product that meets the required specification. Typically these instructions will be written by technical experts, the chemical engineers who were responsible for the technology transfer, the process validation and so on. PharmiWeb.com Field Reporter: Joanna Hills
	Networking Tips 03 Aug 06 Networking: What is it and How do you do it? Jim Melling - Field Reporter
	Preparing for GCP Inspections: The Truth, the Whole Truth, and Nothing But the Truth 02 Aug 06 Every sponsor or CRO can expect their country’s regulatory agency to arrive on their premises periodically to conduct routine inspections. In the UK, for instance, the Medicines and Healthcare products Regulatory Agency (MHRA) conducts routine periodic inspections approximately every three years. Apart from these, the MHRA also conducts “for cause” and “follow up” inspections, and they also take part in the third-country inspection program. Because all inspections may be either announced or unan Triona Coll
	Elidel Eczema Cream: Dr Mark Ballard Answers Our Questions 01 Aug 06 Dr Mark Ballard, the Medical Director of Respiratory and Dermatology Therapeutic Areas at the Novartis Pharmaceuticals Corporation answers our questions about their eczema cream Elidel. Freya Eden-Ellis
	Call for guidelines on when to stop or continue drug treatment for Alzheimer’s Disease 01 Aug 06 Doctors taking part in a survey on Alzheimer’s Disease (AD) management have called for clear and consistent guidelines on diagnosis and treatment of the condition to be drawn up as a matter of urgency. The survey was sponsored by Eisai Europe Ltd and Pfizer Inc, who market the cholinesterase inhibitor Aricept (donepezil), and was presented during the International Conference on Alzheimer’s Disease and Related Disorders. Olwen Glynn Owen – Pharmiweb Field Reporter
	A Full Pipeline of Follow-on TNF-Antagonists 01 Aug 06 The US$ 7.6 bln market of TNF-antagonists attracts numerous follow-on compounds including improved TNF-antagonists and molecules originating from new technologies La Merie Business Intelligence
	Sheltering under an Umbrella? 31 Jul 06 The Treasury is aware of a growing trend, which has recently moved into the pharmaceutical sector, for staff to be provided to clients through “umbrella” or “composite” companies. These companies promise a golden scenario of reduced costs to their clients and greater take-home pay to the individuals who work through them. Claire Jackaman
	Antiarrhythmics: RSD1235 woes reduce market potential but not clinical impact 31 Jul 06 Atrial fibrillation (AF) is the most common form of arrhythmia, or irregular heartbeat, with an estimated nine million sufferers worldwide. Although safe, effective treatment for AF is critical, historically there has been little R&D investment and little innovation in the AF market. However, this may be about to change, with the AF market expected to triple by 2015. Datamonitor
	New Tools for Mental Health Professionals: Computerised Cognitive Behavioural Therapy (CCBT) in Primary Care 25 Jul 06 Cognitive behaviour therapy (CBT) combines two very effective kinds of psychotherapy delivered face to face by medical therapists Jim Melling - PharmiWeb Field Reporter
	Lean Documentation 2b 25 Jul 06 In the last report we analysed part of an SOP control system for inefficiencies and opportunities for error, by mapping the system and asking ‘what if?’ at each stage. But, as we mentioned previously, documentation systems (or, indeed, any type of control system) rarely operate in isolation. So let’s look at some of the inputs and outputs there might be on a typical site, using the same process as before. Joanna Hills - PharmiWeb Field Reporter
	Lean Documentation 2 25 Jul 06 A well-run documentation system will support your business processes and improvements, not hold them back. How do you ensure that this is the case? Joanna Hills - PharmiWeb Field Reporter
	PowderMed: flying ahead in avian flu 21 Jul 06 PowderMed has submitted an application to UK re